

Kyriakos D Economides

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11228973/publications.pdf>

Version: 2024-02-01

8
papers

630
citations

1163117
8
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

873
citing authors

#	ARTICLE	IF	CITATIONS
1	Hoxb13 mutations cause overgrowth of caudal spinal cord and tail vertebrae. <i>Developmental Biology</i> , 2003, 256, 317-330.	2.0	156
2	A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. <i>Molecular Therapy</i> , 2021, 29, 1729-1743.	8.2	152
3	Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. <i>Development (Cambridge)</i> , 2003, 130, 2061-2069.	2.5	146
4	ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance. <i>Communications Biology</i> , 2021, 4, 497.	4.4	73
5	Exosome Surface Display of IL12 Results in Tumor-Retained Pharmacology with Superior Potency and Limited Systemic Exposure Compared with Recombinant IL12. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 523-534.	4.1	50
6	Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs. <i>Nature Biomedical Engineering</i> , 2018, 2, 822-830.	22.5	26
7	Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities. <i>Journal of the American Chemical Society</i> , 2021, 143, 4714-4724.	13.7	18
8	Abstract 944: exoSTING: An engineered exosome therapeutic that selectively delivers STING agonist to the tumor resident antigen-presenting cells resulting in improved tumor antigen-specific adaptive immune response. <i>Cancer Research</i> , 2019, 79, 944-944.	0.9	9